Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Immunomedics
→
Gilead Sciences

Acquisition · Cash · announced Sep 13, 2020

View in network
  1. Announced

    Sep 13, 2020

  2. Closed

    Oct 22, 2020

Economics

Cash()

Pre-deal · pre-deal mark: 2020, year precision · rounding grid ±$100M · Gilead Sciences 8-K filing, SEC EDGAR — Immunomedics acquisition (NASDAQ:IMMU)

$88/share, ~$21B

Target

Immunomedics

Breast Health · Clinical / therapeutic

HQ Morris Plains, NJ · Founded 1982

Developer of Trodelvy (sacituzumab govitecan), first-in-class Trop-2 ADC for metastatic triple-negative breast cancer (mTNBC)

  • Business Wire — Gilead/Immunomedics announcement (Sep 13, 2020)
  • Gilead Sciences press release (Sep 13, 2020)
  • SEC EDGAR — Immunomedics merger filing

Acquirer

Gilead Sciences

Healthcare

HQ Foster City, CA

Biopharmaceutical company expanding into oncology — Trodelvy ADC for triple-negative breast cancer via Immunomedics acquisition

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Trodelvy (sacituzumab govitecan) is first-in-class Trop-2 ADC approved for metastatic triple-negative breast cancer — transforms Gilead's oncology portfolio; >$10B risk-adjusted revenue potential by 2030

Evidence ladder

Dual-source corroborationValue disclosed
  1. Secondary (press / IR)

    Business Wire — Gilead/Immunomedics announcement (Sep 13, 2020)

  2. Secondary (press / IR)

    Gilead Sciences press release

  3. Primary (regulatory / filing)

    SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_8k.htm

    Open source

Limitations

  • $88/share, ~$21B
  • Pre-deal valuation sourced from: Gilead Sciences 8-K filing, SEC EDGAR — Immunomedics acquisition (NASDAQ:IMMU). Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Breast Health

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Insufficient disclosed data

No verified Breast Health deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
BiotheranosticsHologicJan 5, 2021
Focal TherapeuticsHologicSep 26, 2018
Faxitron BiopticsHologicJul 31, 2018
SuperSonic ImagineHologicJun 21, 2019

Other verified deals by Gilead Sciences

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Gilead Sciences are already listed above, or none are in the dataset.

Patient empowerment context

Empowerment context — Immunomedics

Curated survey mapping

HLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.

  • Presented with clinical trial as treatment option (Press release)1 in 5cited HLTH 2022Mapping source →
  • No survivorship care plan after active treatment (Press release)54%cited HLTH 2022Mapping source →
  • Oncologist listens; wishes reflected in treatment plan (Press release)56%cited HLTH 2022Mapping source →
  • Not aware of survivorship resources (Press release)2 in 3cited HLTH 2022Mapping source →

Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Flatiron Health

Full cited gap matrix →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.